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Abstract
Background: Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide. Bleeding can
occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases. The main causes
include peptic ulcer/erosive mucosal disease, oesophageal varices and malignancy. The case fatality rate is
around 10% for upper GI bleeding and 3% for lower GI bleeding. Rebleeding affects 5–40% of patients and is
associated with a four-fold increased risk of death. Tranexamic acid (TXA) decreases bleeding and the need
for blood transfusion in surgery and reduces death due to bleeding in patients with trauma and postpartum
haemorrhage. It reduces bleeding by inhibiting the breakdown of fibrin clots by plasmin. Due to the
methodological weaknesses and small size of the existing trials, the effectiveness and safety of TXA in GI
bleeding is uncertain. The Haemorrhage ALleviation with Tranexamic acid – Intestinal system (HALT-IT) trial
aims to provide reliable evidence about the effects of TXA in acute upper and lower GI bleeding.
Methods: The HALT-IT trial is an international, randomised, double-blind, placebo-controlled trial of tranexamic acid in
12,000 adults (increased from 8000) with acute upper or lower GI bleeding. Eligible patients are randomly allocated to
receive TXA (1-g loading dose followed by 3-g maintenance dose over 24 h) or matching placebo. The main analysis
will compare those randomised to TXA with those randomised to placebo on an intention-to-treat basis, presenting
the results as effect estimates (relative risks) and confidence intervals. The primary outcome is death due to bleeding
within 5 days of randomisation and secondary outcomes are: rebleeding; all-cause and cause-specific mortality;
thromboembolic events; complications; endoscopic, radiological and surgical interventions; blood transfusion
requirements; disability (defined by a measure of patient’s self-care capacity); and number of days spent in intensive
care or high-dependency units. Subgroup analyses for the primary outcome will consider time to treatment, location of
bleeding, cause of bleed and clinical Rockall score.
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Discussion: We present the statistical analysis of the HALT-IT trial. This plan was published before the treatment
allocation was unblinded.
Trial registration: Current Controlled Trials, ID: ISRCTN11225767. Registered on 3 July 2012;
Clinicaltrials.gov, ID: NCT01658124. Registered on 26 July 2012.
Keywords: Gastrointestinal haemorrhage, Tranexamic acid, Clinical trial, Statistical analysis,
Background
Acute gastrointestinal (GI) bleeding is a common med-
ical emergency and an important cause of mortality
worldwide. Bleeding can occur from the upper or lower
GI tract, with upper GI bleeding accounting for most
cases. The incidence varies widely depending on the
population prevalence of risk factors, with a reported in-
cidence of upper GI bleeding of 50–140 per 100,000
across the US, Europe and Scandinavia [1–9]. The case
fatality rate is around 10% for upper GI bleeding [1, 10]
and 3% for lower GI bleeding [11]. Despite evidence sug-
gesting improvements in survival in recent decades, the
case fatality rate for upper GI bleeding varies from 3 to
15%, with the highest risk of death in patients with
upper GI malignancies and varices [1, 3, 4, 8, 10, 12–16].
In addition to cause of bleeding, other factors associated
with mortality include older age, signs of shock, severe
bleeding, active bleeding, rebleeding and extent of co-
morbid disease [16–20].
The main causes of GI bleeding are peptic ulcer dis-
ease, erosive mucosal disease, oesophageal varices and
malignancy [10]. Peptic ulcer disease and erosions due
to Helicobacter pylori infection and non-steroidal anti-
inflammatory drug (NSAID) use are common causes of
GI bleeding worldwide [1, 6, 10, 12, 18, 21–25]. Bleeding
from gastro-oesophageal varices due to liver cirrhosis is
an increasing cause of bleeding in the West, but is also a
major cause in parts of South America, Asia, Africa and
the Middle East where there is high prevalence of hepa-
titis or schistosomiasis [26–33]. Symptoms of GI bleed-
ing include haematemesis and coffee ground vomitus,
melaena and the passage of fresh red blood in the stool,
and clinical signs of shock such as hypotension and
tachycardia.
Some patients with GI bleeding initially stop bleed-
ing and have a brief period of haemodynamic stability
before starting to bleed again. This phenomenon,
known as rebleeding, is common and can affect be-
tween 5 and 40% of patients with acute GI bleeding.
Rebleeding is associated with a four-fold increased
risk of death [10, 11, 16, 17, 34]. Some of the vari-
ation in rebleeding rates may be explained by the use
of different definitions, including fresh haematemesis
or melaena and recurrent hypotension or tachycardia
within varying timeframes of the index bleed [18].
The risk of rebleeding is highest in the days immedi-
ately after the index bleed and declines rapidly with
time [35–37]. The risk factors for rebleeding are re-
lated to the lesion responsible for bleeding, but also
influenced by age, comorbidity and concomitant
medication use. [16, 17].
Tranexamic acid (TXA) reduces clot breakdown by
inhibiting the degradation of fibrin by plasmin. It de-
creases bleeding and the need for blood transfusion in
surgery and reduces death due to bleeding in patients
with traumatic and postpartum haemorrhage [38–40]. A
systematic review and meta-analysis of TXA in patients
with upper GI bleeding included eight randomised trials
with a total of 1702 patients [41]. Although there was a
statistically significant reduction in mortality with TXA
(RR 0.60, 95% CI 0.42–0.87; p = 0.007) and a non-signifi-
cant reduction in rebleeding (RR 0.72, 95% CI 0.50–
1.03), because of methodological weaknesses in the in-
cluded trials and the imprecise effect estimates from
meta-analyses, the effectiveness and safety of TXA in GI
bleeding remains uncertain [41]. Moreover, the included
trials were too small to assess the effect of TXA on
thromboembolic events. The Haemorrhage ALleviation
with Tranexamic acid – Intestinal system (HALT-IT)
trial aims to provide reliable evidence about the effects
of TXA in acute GI bleeding [42].
Methods
Trial design
The HALT-IT trial is an international, randomised,
double-blind (participants and trial staff ), placebo-con-
trolled trial to quantify the effects of TXA on morbidity
and mortality in adults with significant upper or lower
GI bleeding.
Blinding and randomisation
Pfizer Manufacturing, Marketing Authorisation number
PL 00057/0952, manufactures the TXA. Torbay and
South Devon NHS Foundation Trust, Manufacturing
Authorisation number MIA (IMP) 13079, manufactures
the placebo (sodium chloride 0.9%). Sharp Clinical Ser-
vices (UK) Ltd., Manufacturing Authorisation number
MIA (IMP) 10284, manufactures the study drug treat-
ment packs containing either the active drug TXA or
placebo. The Marketing Authorisation guarantees that
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the product is manufactured and released in accordance
with the UK’s Good Manufacturing Practice (GMP) reg-
ulations. Ampoules and packaging are identical in
appearance.
An independent statistician from Sealed Envelope Ltd.
(UK) generates randomisation codes to be sent to Sharp
Clinical Services UK Limited, a GMP-certified clinical
trial supplies company that prepares trial treatment
packs in accordance with the randomisation list. Sharp
Clinical Services conduct the blinding process and first-
stage Qualified Person (QP) release, which involves
complete removal of the original manufacturer’s label
and replacement with the clinical trial label bearing the
randomisation number for use as the pack identification.
Other pack-label text are identical for TXA and placebo
treatments and in compliance with requirements for in-
vestigational medicinal products. Sharp Clinical Services
UK are also responsible for maintaining the Product
Specification File (PSF) until final database lock and
unblinding of the trial data. Quality control checks to as-
sure the blinding process are performed on a random
samples of final QP released drug packs. High-perform-
ance liquid chromatography (HPLC) separation of
known TXA is assessed against blinded samples to con-
firm which ampoule contains the placebo and active
treatment. The tested samples are unblinded to assure
accuracy of blinding.
The Trial Coordinating Centre (TCC) is responsible
for assuring that all relevant approvals are available at
the TCC before release of the trial treatment to a site. A
separate Manual of Operating Procedures details the
drug accountability system. The Investigator’s Brochure
details labelling of the trial treatment and other pro-
cesses for assuring adherence to GMP.
Eligible patients are randomised to receive either TXA
or placebo as soon as possible and the study treatment
started immediately. The next consecutively numbered
treatment pack is taken from a box of eight packs. A
fixed loading dosage of 1 g TXA or placebo (sodium
chloride 0.9%) is administered, followed by a mainten-
ance dose of 3 g TXA or placebo (sodium chloride 0.9%)
infused over 24 h.
Ethics approval and consent
The trial was approved by the UK NRES Committee
East of England (reference number 12/EE/0038), as well
as national and local research ethics committees of par-
ticipating countries outside of the UK.
Acute severe GI bleeding can be a frightening con-
dition for the patient and the ensuing blood loss may
have adverse impact on the patient’s mental and emo-
tional state, impairing their decision-making ability.
The consent procedures consider this together with
the need to randomise and treat urgently. If the
patient is fully competent, written consent is sought.
If the patient’s capacity is impaired and a personal or
professional representative is available, consent is
sought from the representative. If neither are able to
provide informed consent, consent is waived and the
patient is informed about the trial as soon as it is
possible.
Data collection
The entry form (Additional file 1) is used to assess eligi-
bility and collect baseline information. Once a patient
has been randomised, the outcome in hospital is col-
lected even if the trial treatment is interrupted or is not
actually given. No extra tests are required but a short
outcome form (Additional file 1) is completed from the
medical records 28 days after randomisation or on dis-
charge from the randomising hospital or on death
(whichever occurs first). Any adverse events that become
known to the investigator are reported up to 28 days
after randomisation.
Change in primary outcome
We originally specified all-cause mortality as the pri-
mary outcome because we believed that most deaths
would be due to bleeding. However, as the trial was
underway we observed that over half of all deaths
were due to non-bleeding causes such as cancer and
sepsis (see Fig. 1). Tranexamic acid reduces bleeding
by inhibiting fibrinolysis. Based on this mechanism
of action, we do not expect any substantial reduction
in non-bleeding deaths. This hypothesis is supported
by evidence from trials of TXA in trauma and post-
partum haemorrhage [39, 40, 43]. As such, the treat-
ment effect on all-cause mortality will be diluted by
non-bleeding causes of death, reducing statistical
power [43].
Death due to bleeding is the relevant endpoint for the
HALT-IT trial because it has the potential to be reduced
by the trial treatment. Fibrinolysis may play an import-
ant role in GI bleeding: gastric vein blood samples from
patients with peptic ulcers contain high concentrations
of plasmin and many patients with acute upper GI
bleeding have elevated levels of fibrin degradation prod-
ucts (a biomarker for fibrinolysis) which is associated
with worse outcomes [44–46].
Cause of death is assigned by local investigators and a
narrative of the events leading to death is reviewed by
the principal investigator (who is blind to treatment allo-
cation) and queried as necessary to verify cause of death.
Due to the double-blind nature of the trial, the coding of
the cause of death cannot be affected by the patient’s
randomised group.
We also originally specified that the primary outcome
would be measured up to 28 days after randomisation.
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However, patients receive TXA (or placebo) for their ini-
tial bleed but not for rebleeding episodes. Tranexamic
acid has a half-life of 2–3 h so 99% will be eliminated
within about 2 days of randomisation [47, 48]. We do
not expect TXA to reduce deaths from a rebleeding epi-
sode for several weeks after the drug has been fully elim-
inated, therefore the primary outcome will consider
early deaths due to bleeding only, defined as those that
occur within 5 days of randomisation.
The rationale for refining the primary outcome from
all-cause mortality to death due to bleeding was pub-
lished in October 2018 [43]. The decision was supported
by the Trial Steering Committee and was made prior to
the end of the trial and prior to unblinding and so was
not a data-dependent change.
Sample size
The sample size calculation for the trial was based on
the original primary outcome of all-cause mortality [42].
While the trial was underway, accumulating evidence
from other large trials of TXA showed no apparent ef-
fect on non-bleeding causes of death [39, 40]. Because a
considerable proportion of deaths in the HALT-IT trial
are due to non-bleeding causes, the sample size was in-
creased from 8000 to 12,000 to retain sufficient power
for all-cause mortality. However, our assumptions were
too generous – we assumed that 60% of deaths would be
due to bleeding by the end of the trial rather than 40%
(assuming a control group event rate of 10%, a study
with 12,000 participants would have over 80% power to
detect a 15% (RR = 0.6 × 0.75 + 0.4 × 1.0 = 0.85) reduction
in all-cause mortality). Based on the refined primary
outcome, assuming a cumulative incidence of death due
to bleeding of 4%, a study with 12,000 patients will have
about 85% power (two-sided alpha = 5%) to detect a clin-
ically important 25% relative reduction in death due to
bleeding from 4 to 3%. Loss to follow-up is expected to
be less than 1% (it was 0.16% in the World Maternal
Antifibrinolytic (WOMAN) trial) so was not taken into
consideration when calculating the sample size. This
power calculation is based on the primary analysis and
refers to the unadjusted chi-squared test.
Trial population
Eligibility
Patients with significant GI bleeding to whom the uncer-
tainty principle applies are eligible. Specifically, a patient
can be enrolled if the responsible clinician is substan-
tially uncertain as to whether the trial treatment is ap-
propriate for that particular patient. Significant bleeding
is diagnosed clinically and implies a risk of bleeding to
death. Patients with significant bleeding may include
those with hypotension, tachycardia, signs of shock, or
those needing urgent transfusion, endoscopy or surgery.
Patients with a clear indication (e.g. traumatic haemor-
rhage) or contraindication (e.g. history of convulsions,
thromboembolic disease) for TXA are excluded.
Recruitment, withdrawal and loss to follow-up
We will display the flow of study participants using a
Consolidated Standards of Reporting Trials (CONSORT)
Diagram (see Additional file 1: Figure S1). For each trial
arm, we will present the total number randomised, the
number with baseline data, the number lost to follow-
Fig. 1 Causes of death in the Haemorrhage ALleviation with Tranexamic acid – Intestinal system (HALT-IT) trial during recruitment
(November 2018)
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up, the number who withdrew consent, and the number
of participants with outcome data.
Baseline patient characteristics
We collect data on the following baseline characteris-
tics: age, biological sex, time from onset of GI bleed-
ing symptoms to randomisation, suspected location of
bleeding, clinical symptoms (e.g. haematemesis, me-
laena), suspected variceal bleeding, systolic blood
pressure (SBP) , heart rate (HR), signs of shock, sus-
pected active bleeding, major comorbidities, anticoa-
gulation therapy and type of admission. We will
present the distribution of baseline characteristics (n
and %) in the treatment and placebo groups to check
that randomisation was successful in producing simi-
lar groups (see Additional file 1: Table S1).
Analysis
Primary analysis
The main analyses will compare those allocated TXA with
those allocated placebo on a modified intention-to-treat
basis, excluding patients who received neither dose of the
allocated trial treatment. We will present the results as ef-
fect estimates (relative risks) with a measure of precision
(95% confidence intervals) (see Additional file 1: Table S2).
Additionally, we will present results of the primary analysis
adjusted for all baseline covariates. If baseline covariates are
associated with the outcome, adjusting for any chance im-
balances in baseline risk will increase statistical power. We
will not present risk differences because they are not a gen-
eralisable measure of the treatment effect and are
dependent on baseline risk. The effect of TXA will also be
examined graphically using cumulative incidence curves
presented with their associated hazard ratios and log-rank
p values (see Additional file 1: Figure S2) [49]. The effects
of TXA on death due to bleeding in the HALT-IT trial will
be set in the context of other trials of TXA for acute severe
haemorrhage (the CRASH-2 and WOMAN trials).
Primary outcome
Death due to bleeding within 5 days of randomisation is
the primary outcome. As outlined in the section ‘Change
in primary outcome’ above, cause of death is assigned by
local investigators who provide a narrative of the events
leading to death. The cause of death narratives are
reviewed by the principal investigator (who is blind to
treatment allocation) and queried if more information is
needed to confirm whether death is due to bleeding or
another cause. Furthermore, due to double-blind nature
of the trial, the coding of the cause of death cannot be
affected by the patient’s randomised group. For more de-
tails, please see accompanying information in the section
‘Change of primary outcome’.
Secondary outcomes
We will assess the effect of TXA on the following sec-
ondary outcomes. Unadjusted analyses will be presented
in the main text and although we do not expect any
baseline imbalances, to complement the unadjusted ana-
lyses and potentially increase statistical power (if covari-
ates are associated with the outcome) we will present
results of the analyses adjusted for all baseline covariates
in an appendix.
Rebleeding
Rebleeding generally occurs in approximately 10–25% of
patients with acute GI haemorrhage and is associated
with an increased risk of death due to bleeding [50]. A
clinical diagnosis of rebleeding is made by the treating
clinician based on the presence of any of the following
criteria, as defined in a data collection guide. These cri-
teria for rebleeding were recommended by a methodo-
logical framework for trials in GI bleeding following an
international consensus conference [51]:
 Haematemesis or bloody nasogastric aspirate > 6 h
after endoscopy
 Melaena after normalisation of stool colour
 Haematochezia after normalisation of stool colour
or after melaena
 Development of tachycardia (HR > 110 beats per
min) or hypotension (SBP ≤ 90 mmHg) after ≥ 1 h of
haemodynamic stability (i.e. no tachycardia or
hypotension) in the absence of an alternative
explanation for haemodynamic instability such as
sepsis, cardiogenic shock, or medication
 Haemoglobin drop of > 2 g/dl after two consecutive
stable values (< 0.5 g/dl decrease) ≥3 h apart
 Tachycardia or hypotension that does not resolve
within 8 h after index endoscopy despite appropriate
resuscitation (in the absence of an alternative
explanation) associated with persistent melaena or
haematochezia
 Persistently dropping haemoglobin of > 3 g/dl in 24 h
associated with persistent melaena or haematochezia
It should be noted that patients may continue to
have haemodynamic instability, falling haemoglobin
levels or persistent melaena or rectal bleeding for
hours and even days after bleeding has stopped, mak-
ing these patients difficult to categorise; however,
these criteria are more likely to indicate rebleeding
than equilibration [51].
Most rebleeding tends to occur within 5 days of the
index bleed [35–37]. We believe that TXA will be
most effective at reducing the risk of rebleeding soon
after the index bleed when blood plasma concentra-
tions of the drug are above the level needed to inhibit
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fibrinolysis [52]. To assess whether TXA reduces
rebleeding, we will analyse the effect on early rebleed-
ing within 5 days of randomisation (see Additional file
1: Table S2).
Although rebleeding is most common within the
first 5 days after the index bleed, TXA will have been
metabolised within about 2 days of randomisation,
with the blood plasma concentration falling below
the level needed to inhibit fibrinolysis within around
24 h. As such, we will examine the effect on rebleed-
ing within 24 h of randomisation. We hypothesise
that TXA will be less effective for late rebleeding oc-
curring days or weeks after the drug has been elimi-
nated. To investigate this we will assess the effect of
TXA on rebleeding within 28 days (see Additional
file 1: Table S2). If our hypothesis is correct, the in-
clusion of late rebleeding events should dilute the
treatment effect.
Death due to bleeding within 24 h and 28 days
Tranexamic acid will be eliminated within about 2
days of randomisation, with blood plasma levels fall-
ing below those needed to inhibit fibrinolysis within
around 24 h. Furthermore, patients with acute GI
haemorrhage bleed to death quickly, with many
deaths due to bleeding occurring within the first
day. Evidence from other trials suggests that this is
where the greatest treatment benefit will be ob-
served. As such, we will analyse the effect of TXA
on deaths due to bleeding within 24 h of randomisa-
tion. Conversely, because there may be a weaker
treatment effect on late deaths due to bleeding that
occur several days or weeks after randomisation, we
will also analyse the effect on death due to bleeding
within 28 days of randomisation (see Additional file
1: Table S2). We expect to observe a smaller treat-
ment effect when including late bleeding deaths due
to dilution towards the null.
Mortality
We will analyse the effect of TXA on all-cause and
cause-specific mortality at 28 days. Specific causes of
death to be analysed include death due to bleeding,
thrombosis, organ failure, pneumonia, sepsis, malig-
nancy and other causes (see Additional file 1: Table
S3). We will also examine the temporal distribution
of causes of death by days since randomisation using
a frequency bar chart (see Additional file 1: Figure
S3). Based on its mechanism of action and data from
large randomised trials, we do not expect TXA to re-
duce deaths from non-bleeding causes like cancer or
sepsis or to reduce late deaths from bleeding.
Endoscopic, radiological and surgical procedures for GI
bleeding
We will assess the effect of TXA on diagnostic and
therapeutic endoscopic and radiological procedures and
surgical interventions (see Additional file 1: Table S5). It
remains unclear whether TXA reduces the need for sur-
gery in GI bleeding [41]. In large trials of TXA for post-
partum and traumatic haemorrhage, there was no
evidence of an effect on surgical interventions except for
laparotomy for bleeding [39, 40]. If TXA reduces GI
bleeding, it has the potential to reduce the need for some
endoscopic, radiological and surgical procedures. While
we do not expect TXA to influence diagnostic endoscopic
and radiological procedures planned around the time of
hospital admission and randomisation, there is potential
to reduce the need for diagnostic procedures planned after
resuscitation, and, therefore, after randomisation [43].
Similarly, therapeutic procedures and surgical interven-
tions planned and undertaken after diagnosis also have
the potential to be influenced by TXA. It is not possible to
look at procedures by time as this information was not re-
corded, and although type of procedure can be used as a
rough indication of timing, therapeutic or surgical proce-
dures planned around the time of randomisation could
still dilute the effect estimates towards the null.
Blood transfusion
Since blood transfusion is mostly determined by blood
loss prior to randomisation, we do not expect to see a
marked reduction in the need for blood transfusion with
the use of TXA [43]. Major haemorrhage protocols dic-
tate the type and volume of blood components that pa-
tients receive based on presenting clinical signs such as
blood pressure and estimated blood loss. Furthermore,
survivor bias could lead to higher transfusion rates in
the TXA group. In keeping with this, a systematic review
of TXA for GI bleeding found no reduction in transfu-
sion [41]. Although TXA has the potential to reduce
transfusion for blood lost after randomisation, e.g. after
rebleeding, we did not collect data on date and time of
transfusion. Any effect on late transfusions is likely to be
obscured by early transfusions for blood lost pre-ran-
domisation. We will assess the effect of TXA on the use
of whole blood or packed red cells, frozen plasma and
platelets comparing the frequency of transfusion and the
mean number of (adult-equivalent) units transfused (see
Additional file 1: Table S5).
Thromboembolic events
An individual patient data meta-analysis of the
WOMAN and CRASH-2 trials found evidence of a re-
duction in myocardial infarction with TXA (OR = 0·64,
95% CI 0·43–0·97; p = 0·037) and no evidence of an in-
creased risk of fatal vascular occlusive events (OR 0·73,
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95% CI 0·49–1·09; p = 0·120) or other non-fatal events
[53]. While this finding is reassuring, we cannot exclude
the possibility of some increased risk with TXA, particu-
larly as patients with GI bleeding are older than those
with traumatic or postpartum haemorrhage and many
have multiple comorbidities. Older age is associated with
a pro-coagulation haemostatic profile including elevated
fibrinogen and plasminogen activator inhibitor 1 and re-
duced clotting time [54–56]. A systematic review of
TXA for the treatment of upper GI bleeding found no
evidence for a difference in the risk of thromboembolic
events but lacked power [41]. We will examine the effect
of TXA on fatal and non-fatal pulmonary embolism,
deep vein thrombosis, stroke and myocardial infarction
(see Additional file 1: Table S6).
Complications
We will analyse the effect of TXA on renal, hepatic
and respiratory failure, cardiac events, sepsis, pneu-
monia and seizures (see Additional file 1: Table S6).
If TXA reduces death due to bleeding, patients in the
tranexamic group will survive for longer on average
and may, therefore, be at greater risk of complications
such as sepsis, pneumonia and organ failure. Gener-
ally, death due to bleeding tends to occur soon after
bleeding onset whereas infections and organ failure
take several days to occur. On the other hand, if
TXA reduces bleeding it may reduce liver failure be-
cause bleeding can lead to the deterioration of liver
function. Although there is evidence that high-dose
TXA can cause seizures, we do not expect to see an
increase in seizures with the low dose given in the
trial.
Self-care capacity
Patients self-care capacity will be measured using the
Katz Index of Independence in Activities of Daily Living
(Katz ADL) [57]. Participants’ performance in six func-
tions (bathing, dressing, toileting, transferring, contin-
ence and feeding) is assessed at the time of discharge
from the randomising hospital or in hospital 28 days
after randomisation. A score of 1 is assigned to each
function the individual can perform independently and
they are summed to produce a total score. A score of 6
suggests full function, 4 suggests moderate impairment,
and 2 or less suggests severe functional impairment. We
expect that reduced blood loss in patients who receive
TXA will result in less functional impairment. That said,
it is possible that patients in the treatment group will be
discharged faster which could mask improvements in
self-care capacity at the time of discharge. To assess this
hypothesis we will compare the difference in mean Katz
ADL score in survivors in the TXA and placebo groups
as well as the proportion of patients with no impairment
(6), mild to moderate impairment (3–5) or severe im-
pairment (0–2), (see Additional file 1: Table S6).
Days spent in the intensive care or high-dependency unit
We will analyse the effect of TXA on number of days
spent in the intensive care unit (ICU) or high-de-
pendency unit (HDU). We will compare the difference
in mean number of days spent in the ICU or HDU in
the TXA and placebo groups (see Additional file 1:
Table S6). Because beds in these units can be limited,
we may not see an effect on this outcome measure.
Adverse events
Data on the number of adverse events (AEs), serious ad-
verse events (SAEs) and suspected unexpected serious
adverse reactions (SUSARs) reported up to 28 days after
randomisation will be presented. We will present a sum-
mary table in an Additional file 1 to describe the type of
AE, Medical Dictionary for Regulatory Activities (Med-
DRA) preferred term (PT), MedDRA system organ class
(SOC) and the number of occurrences and outcomes
(completely recovered, recovered with sequelae, or died)
in the TXA and placebo groups. With events grouped by
MedDRA SOC, we will compare the frequency of events
between trial arms using an unadjusted modified Poisson
regression model (see Additional file 1: Table S7). AEs
with evidence that they may be increased by TXA (i.e.
seizures and thromboembolic events), will be analysed
on an individual basis as well as recurrent episodes of
GI bleeding reported as AEs.
Subgroup analyses
We will conduct the following subgroup analyses for
the primary outcome of death due to bleeding: time
to treatment, location of bleeding, cause of bleeding
and clinical Rockall score. We will fit interaction
terms with randomised group in a Poisson regression
model with robust error variance from the sandwich
estimator [58]. Interaction tests (the Wald test) will
be used to explore whether the effect of treatment (if
any) differs across these subgroups. Results will be
presented as unadjusted and adjusted effect estimates
with a measure of precision (95% confidence inter-
vals) and p value for the test for interaction (see Add-
itional file 1: Table S4). Except for time to treatment,
statistically significant heterogeneity between sub-
groups is required, as determined by the test for
interaction p value, and not just statistical significance
of a result in a specific subgroup [59].
Although treatment group is randomised within
subgroups, the factors defining subgroups are not rando-
mised. Several baseline characteristics are associated with
the subgroup variables. For example, early treatment is
correlated with bleed characteristics and patient
Brenner et al. Trials          (2019) 20:467 Page 7 of 13
characteristics (see Fig. 2), some of which confer a higher
clinical Rockall score, suggesting that patients with more
severe bleeding are treated earlier. Since these factors are
also associated with mortality, they could potentially con-
found the interaction between time to treatment and the
treatment effect.
If TXA is shown to be effective and the treatment ef-
fect varies by time to treatment, there is potential to
intervene on time to treatment in order to increase the
treatment effect. Although we cannot intervene on loca-
tion of bleeding, cause of bleeding or clinical Rockall
score, we are interested in ascertaining causal interaction
of these factors with the treatment effect rather than
simply assessing effect heterogeneity. As such, we will
adjust all subgroup analyses for potential confounders
[60]. Selection of potential confounders is based upon
review of unblinded data within the trial to date in order
to identify prognostic baseline characteristics that are as-
sociated with the subgroup variables. Potential con-
founders include age, time to treatment, SBP, HR, signs
of shock, location of bleeding, suspected active bleeding,
comorbid liver disease and suspected variceal bleeding.
Signs of shock may be collinear with HR or blood pres-
sure, and suspected variceal bleeding may be collinear
with comorbid liver disease – if so, signs of shock and
suspected variceal bleeding will not be included in the
models. The final models remain to be determined be-
cause the outcome of interest is the treatment effect and
the association between the potential confounders and
the treatment effect cannot be assessed before
unblinding.
Time to treatment (≤ 3 h, > 3 h)
Trials of TXA in traumatic and postpartum haemor-
rhage provide evidence that early treatment (within 3
h of bleeding onset) confers the most benefit, while
late treatment is ineffective [39, 53, 61]. As such, we
plan to conduct a subgroup analysis of the treatment
effect stratified by time to treatment. Patients with GI
bleeding may not experience symptoms immediately
so time of symptom onset may not accurately reflect
time of bleeding onset. Time to treatment may, there-
fore, be underestimated. Because few patients are
treated early (within 3 h), there may be low power to
detect an interaction if one exists. As such, we will
analyse time to treatment as both a categorical (≤ 3 h,
> 3 h) and continuous variable because the latter will
preserve more information so should have more
power. However, a limitation of modelling time to
treatment as a continuous variable is the need to spe-
cify the form of the association. To assess non-linear-
ities, we will fit a logistic regression model and use a
likelihood ratio test. Any differences between the two
approaches will be noted.
There is strong prior evidence to expect a time-to-
treatment interaction, with early treatment conferring a
greater benefit and late treatment being ineffective and
possible even harmful [53, 61]. As such, for the
Fig. 2 Potential confounding factors in the subgroup analysis of time to treatment
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subgroup analysis of time to treatment we do not re-
quire as strong evidence against the null hypothesis of
homogeneity as we might usually require. Most trials
lack power to detect heterogeneity in treatment effects
and the lack of a statistically significant interaction does
not mean that the overall treatment effect applies to all
patients. Due to prior evidence that early treatment is
more effective, we will consider the time to treatment
subgroup analysis in the context of the existing data (in
particular data from the CRASH-2 and WOMAN trials)
on the time-to-treatment interaction and will rely more
on scientific judgment than on statistical tests.
Location of bleeding (upper GI, lower GI)
We will examine the effect of TXA on death due to
bleeding stratified by location (upper versus lower GI).
Evidence suggests the rates of rebleeding and mortality
after upper and lower GI bleeding are similar [34], and
there is no reason to expect the effect of TXA to vary
substantially by location of bleeding in the GI tract. Un-
less there is strong evidence against the null hypothesis
of homogeneity of effects (i.e. p < 0.01), the overall rela-
tive risk will be considered the most reliable guide to the
approximate treatment effect in all patients.
Suspected variceal bleeding and comorbid liver disease
(yes, no/unknown)
Outcomes in acute GI bleeding vary by cause of haemor-
rhage. Variceal bleeding is associated with the highest risk
of rebleeding and death. Oesophageal varices are dilated
submucosal veins that usually develop because of portal
hypertension, often due to cirrhosis. Haemostasis is dis-
turbed in patients with liver disease because many of the
pro- and anti-coagulation factors and components of the
fibrinolytic system are produced by hepatic parenchymal
cells in the liver, although the overall sum of effects are
debated [62–64]. Any resulting imbalance in coagulation
or fibrinolysis may alter the antifibrinolytic activity of
TXA; however, the direction of this potential effect re-
mains to be determined. We will examine the effects of
TXA on death due to bleeding in patients with suspected
variceal bleeding and comorbid liver disease compared to
other or unknown causes of bleeding. Unless there is
strong evidence against the null hypothesis of homogen-
eity of effects (i.e. p < 0.01), the overall relative risk will be
considered the most appropriate measure of effect.
Clinical Rockall score (1–2, 3–4, 5–7)
We will assess the effect of TXA stratified by the clinical
(pre-endoscopy) Rockall score, a widely used risk scoring
system for GI bleeding. The score is derived from age,
comorbidities, signs of shock, HR and SBP, all of which
are independent predictors of mortality. Although ori-
ginally developed for upper GI bleeding [17], the Rockall
score has also been shown to be predictive of mortality
in lower GI bleeding [34]. We do not expect the treat-
ment effect to vary by Rockall score. Unless there is
strong evidence of an interaction (p < 0.01), we will
present the overall relative risk as the most appropriate
measure of effect.
Missing data
Based on the data collected to date, we expect loss to
follow-up to be minimal (i.e. less than 1% missing data
on the primary outcome). Any missing values will be re-
ported but not imputed.
Other analyses to be reported in separate
publications
Survival analysis to investigate the timing and duration of
the treatment effect
We will conduct a survival analysis to explore the effect
of TXA on rebleeding and death due to bleeding in
more detail. In large trials of TXA for traumatic
(CRASH-2) and postpartum haemorrhage (WOMAN),
there were few late-bleeding-related events. The precise
timing and duration of TXA’s antifibrinolytic effect re-
main to be determined. For example, it is unclear
whether the treatment effect persists after the drug has
been eliminated. Bleeding-related events occur later in
acute GI bleeding, partly due to rebleeding, so the
HALT-IT trial presents a unique opportunity to investi-
gate this question.
We will report the median survival time and the
cumulative incidence in the treatment and placebo
groups, and model the treatment effect. Cox propor-
tional hazards modelling assumes the hazards in the
treatment and placebo groups are proportional over
time. This assumption may be invalid if the antifibri-
nolytic effect of TXA declines over time as the drug
is metabolised. We will formally assess this using the
Royston-Palmer test for proportional hazards – a
combined test with increased power when an early
treatment effect is present [65]. If the treatment effect
on death due to bleeding and rebleeding appears to
change with time (non-proportional hazards), we will
examine this in detail using various methods. We will
estimate average cumulative hazard ratios for increas-
ingly longer periods of follow-up. This method is
preferred to period-specific hazard ratios, which can
be susceptible to selection bias [66]. Nevertheless, we
will also use Lexis expansion to calculate period-spe-
cific hazard ratios and test for interactions between
treatment group and period. If we are able to identify
the average duration of the treatment effect, we will
examine whether this varies by baseline characteristics
including time to treatment, bleeding severity, cause
of bleeding and age. We will also assess how the
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treatment effect changes with time by including a
time-by-treatment interaction term in the model. Re-
sidual methods will be used to test the assumption of
linear time (first order trend) by plotting Martingale
residuals against continuous covariates.
Death due to bleeding is a competing risk for non-
bleeding causes of death and vice versa. Death is also a
competing risk for rebleeding. We will estimate the treat-
ment effect using a proportional cause-specific hazards
model in which competing events are censored. The
proportional cause-specific hazards model is preferred for
aetiological research; however, both the cause-specific haz-
ard and cumulative incidence can provide insights into a
treatment’s effects [67, 68]. As such, a subdistribution
hazards model and Gray’s test for comparing cumulative
incidence functions will be presented as a supplementary
analysis [69, 70]. Risk of rebleeding is highest immediately
after the index bleed, death is a competing risk for
rebleeding and some patients may experience more than
one episode during the follow-up period. A survival
analysis of the effect of TXA on rebleeding will take into
account timing of events and competing risks.
Cost effectiveness analysis
If the trial demonstrates that TXA is an effective treat-
ment for GI bleeding, we will conduct an economic
evaluation to determine cost-effectiveness. Broadly
speaking the methods will mirror those used by Li et al.
who assessed the cost-effectiveness of TXA for the treat-
ment of women with postpartum haemorrhage [71].
The analysis will compare TXA against clinical practice
without TXA. A cost-utility analysis will be performed
from a health services cost perspective with outcomes
expressed as Quality-adjusted Life Years (QALYs). The
analyses will be performed separately for a set of different
countries, depending on where the majority of people
have been recruited, but is likely to include at least the UK
and Pakistan. A decision model will be used to extrapolate
results from the trial into the longer term. Resource data,
such as drugs and length of inpatient stay, are collected as
part of the trial and will be analysed accordingly. Both de-
terministic and probabilistic sensitivity analysis will be
undertaken. Results will also be presented by subgroups if
considered appropriate.
Impact of baseline risk on treatment effectiveness
To assess whether the effect of TXA on death due to
bleeding varies by baseline risk we will build a prognostic
model using baseline characteristics identified as import-
ant predictors of death due to bleeding. Prognostic factors
include age, SBP, HR, suspected location of bleeding, hae-
metamesis/coffee ground vomitus, suspected variceal
bleeding, suspected active bleeding, comorbidities and
country. The prognostic model will then be used to
stratify patients by risk of mortality and stratum-specific
effect estimates (relative risk) and 95% confidence
intervals will be calculated. We do not expect the treat-
ment effect to vary by baseline risk. Unless there is strong
evidence against the null hypothesis of homogeneity of
effects (p < 0.01), the overall relative risk will be consid-
ered the most reliable guide to the approximate treatment
effect in all patients.
Adjustment for baseline risk
Due to the large size of the HALT-IT trial, baseline
characteristics should be well balanced between the
treatment and placebo groups so that any difference
in outcomes is due to the treatment. There is still a
small possibility, however, that some imbalance in
baseline risk may have arisen by chance. If prognostic
factors are distributed differently across the treatment
and placebo groups, this could bias the treatment ef-
fect. To investigate this hypothesis, we will conduct
an analysis of the treatment effect on death due to
bleeding adjusted for baseline risk. Patients will be
stratified by risk deciles based on the predicted prob-
ability of death due to bleeding and a pooled effect
estimate (relative risk) will be calculated using inverse
variance weighting. This will provide an estimate of
the treatment effect where both groups have equal
baseline risks.
Centre and country effects
Centre- and country-level characteristics can influence
patient outcomes. Differences in outcome may be related
to resource availability or clinical practice. To explore
between-country differences we will present a graph
showing the number of patients and bleeding deaths by
country and will use multivariable regression modelling
to examine the treatment effect by country, including an
interaction term between country and treatment. We
will not adjust for clustering as we expect the effects of
clustering to be small. Because we aim to understand
any between-country differences in the treatment effect,
we will adjust for potential confounders including age,
SBP, HR, comorbidities, location of bleeding, suspected
variceal bleeding, suspected active bleeding and time to
treatment. A comparison between low-, middle- and
high-income countries will be included using the World
Bank country groupings by income. We do not expect
the effect of TXA on the risk of death due to bleeding to
vary by country, even though the absolute risk will vary
due to between-country differences in patient popula-
tions. Countries recruiting fewer than 100 patients will
be omitted from the analysis as necessary.
Between-centre differences in outcome may also
influence the estimation of the treatment effect. We will
first use a mixed-effects regression model using restricted
Brenner et al. Trials          (2019) 20:467 Page 10 of 13
maximum likelihood estimation to examine whether there
are differences in death due to bleeding between centres.
Results will be presented in the form of a forest plot.
Prognostic patient characteristics (age, SBP, HR, comor-
bidities, location of bleeding, suspected variceal bleeding,
suspected active bleeding), treatment group and time to
treatment will be adjusted for. To take into account coun-
try-level effects we will also consider between-centre dif-
ferences in outcome adjusted for country. We will then
use mixed-effects regression to estimate the treatment
effect before and after accounting for between-centre dif-
ferences, assuming a constant treatment effect across
centres. To assess whether the treatment effect differs by
centre, we will fit a model with an interaction term be-
tween centre and treatment.
Data monitoring
The progress of the HALT-IT trial, including recruitment,
data quality, outcomes and safety data, are reviewed by an
independent Data Monitoring Committee, which can de-
cide to reveal unblinded results to the Trial Steering Com-
mittee. To date, four interim analyses have been conducted.
Data sharing
To maximise data utilisation and improve patient care, the
trial data will be made available via our online data-sharing
portal – The Free Bank of Injury and Emergency Research
Data (freeBIRD) (https://ctu-app.lshtm.ac.uk/freebird/) –
once primary and secondary analyses have been published.
Trial status
The study has been actively recruiting since July 2013.
End of recruitment is planned for 31 May 2019, with
end of follow-up expected on 30 June 2019. Further in-
formation is available at http://haltit.Lshtm.ac.uk/.
Discussion
We present our plan for the statistical analysis of the
HALT-IT trial prior to the end of recruitment, database
lock and unblinding in order to avoid data-dependent ana-
lyses. We set out a-priori hypotheses and propose ways to
test these. We also provide the rationale for changing the
primary outcome from all-cause mortality to death due to
bleeding within 5 days of randomisation.
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